BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Canaccord Adams Global Growth Conference
Franklin, Tenn. – August 8, 2008 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Charles E. Hart, CSO, will provide an update of corporate activities at the Canaccord Adams 28th Annual Global Growth Conference. The presentation will take place at the Intercontinental Hotel in Boston on Wednesday, August 13 at 4:00 p.m. EDT.
A live audio webcast of the presentation will be available at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BMTI&item_id=1887611 and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in 2005 for its first product, GEM 21S, for regeneration of bone and periodontal tissue loss resulting from periodontal disease. Currently, the Company has clinical trials ongoing with its product candidates Augment™ Bone Graft (formerly GEM OS1) and Augment™ Injectable Bone Graft (formerly GEM OS2) in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's lead product candidates all combine recombinant human platelet derived growth factors (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
GEM 21S® is a registered trademark of Luitpold Pharmaceuticals, Inc., who owns and markets that product through its Osteohealth Company division for use in periodontal and cranio-maxillofacial applications.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
